Developer docs
API playgroundTry for free, no card

Search company profiles

Kezar Life Sciences

Full company profile

uuid00042yj

Namestring
Kezar Life Sciences
Legal namestring
Kezar Life Sciences, Inc.
Company typeenum
Public
Founded yearint
2015
Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule therapeutics, immunoproteasome inhibitors, autoimmune disease drugs, protein secretion modulators, clinical-stage biotechnology
Industry1 code
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-Stage Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotechnology company focused on developing small molecule therapeutics for autoimmunity and cancer. The company had no revenue and was operating at a loss as it advanced its pipeline of drug candidates through clinical development.

gurufocus.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kezar Life Sciences is a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics that target protein homeostasis pathways. Its lead candidate, zetomipzomib (KZR-616), is a selective immunoproteasome inhibitor being studied for autoimmune diseases including autoimmune hepatitis, lupus nephritis, and systemic lupus erythematosus. The company also advanced a protein secretion (Sec61 translocon) research program for oncology applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Biochemical remission demonstrated in autoimmune hepatitis patients in Phase 2a PORTOLA trial
+2 more records
Product overview1 text field

Kezar Life Sciences was a clinical-stage biotechnology company focused on developing small molecule therapeutics for autoimmunity and cancer. The company's portfolio centered on zetomipzomib (KZR-616), a first-in-class immunoproteasome inhibitor in development for autoimmune hepatitis, lupus nephritis, and systemic lupus erythematosus. Prior to its acquisition by Aurinia Pharmaceuticals, Kezar also maintained a SEC61 inhibitor program (KZR-261) which was sold to Enodia Therapeutics. The company operated at a loss with no revenue and was subsequently acquired in 2026.

Product and service3 records
1Zetomipzomib (KZR-616)
CategoryImmunoproteasome inhibitor therapeutic
Description

A first-in-class selective immunoproteasome inhibitor small molecule being evaluated as a therapeutic for autoimmune hepatitis, lupus nephritis, and systemic lupus erythematosus.

2KZR-261
CategorySec61 translocon inhibitor therapeutic
Description

A small molecule inhibitor of the Sec61 translocon being developed for oncology indications in solid tumors.

3Sec61 Translocon Research Program
CategoryDrug discovery research program
Description

A discovery-stage research program developing small molecule modulators of the Sec61 translocon to disrupt protein secretion in disease-driving cells, targeting oncology and immunology indications.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-30
Description

Aurinia Pharmaceuticals acquired Kezar Life Sciences for $6.955 per share in cash plus one non-transferable contingent value right. The acquisition provided Aurinia access to Kezar's lead product candidate zetomipzomib, a first-in-class immunoproteasome inhibitor in development for autoimmune hepatitis, lupus nephritis, and systemic lupus erythematosus. The transaction was expected to close in Q2 2026.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-03-12
Description

Enodia Therapeutics, a Paris-based developer of small-molecule therapies for protein degradation, acquired Kezar's Sec61-based discovery and development program for $1 million upfront plus up to $127 million in potential milestone payments and royalties. The acquisition enabled Enodia to leverage nearly a decade of Kezar's Sec61 translocon research to advance its targeted protein degradation platform.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Travere Therapeutics develops therapeutics for rare diseases including FSGS and other immune-mediated kidney conditions. Comparable in addressing serious autoimmune/immune-mediated renal disease and operating as a focused specialty pharmaceutical company in adjacent autoimmune indications.

2ChemoCentryx
TypeBroad incumbent
Description

ChemoCentryx developed TAVNEOS (avacopan) for ANCA-associated vasculitis and was acquired by Amgen in 2022. Comparable clinical-stage autoimmune small-molecule company with a similar trajectory from clinical development through acquisition by a larger pharmaceutical company.

TypeDirect peer
Description

Cabaletta is a clinical-stage immunology company developing cell therapies (CAR-T) for autoimmune diseases including lupus nephritis. Like Kezar, it targets autoimmune indications with significant unmet need and operates in the same South San Francisco biotech ecosystem with similar development-stage economics.

TypeEmerging player
Description

ProKidney is a clinical-stage biotech with limited overlap to Kezar's autoimmune focus but comparable profile as a publicly traded, clinical-stage biotech that underwent restructuring and workforce reductions amid development setbacks.

TypeEmerging player
Description

Arcturus Therapeutics is a clinical-stage biotech developing RNA-based therapeutics including for autoimmune and inflammatory diseases. While technology (mRNA vs. small molecule) differs, it shares the clinical-stage autoimmune development profile and public-company structure with Kezar.

TypeDirect peer
Description

Aurinia developed and commercialized LUPKYNIS (voclosporin) for lupus nephritis, directly overlapping with Kezar's lead indication. Aurinia is now Kezar's acquirer and will integrate zetomipzomib into its autoimmune franchise, making it the most directly comparable peer in clinical-stage/commercial lupus nephritis drug development.

TypeDirect peer
Description

Kyverna is a clinical-stage biotech developing CAR-T cell therapies for autoimmune diseases including lupus nephritis and other immune-mediated disorders. It directly competes with Kezar's lupus nephritis indication using a different modality (cell therapy vs. small molecule).

TypeDirect peer
Description

Alpine Immune Sciences developed protein-based immunotherapies for autoimmune and inflammatory diseases, including povetacicept for autoimmune conditions. Acquired by Vertex in 2024 — directly comparable clinical-stage autoimmune biotech with similar acquisition-exit trajectory to Kezar.

TypeDirect peer
Description

Keros Therapeutics is a clinical-stage biotech developing therapeutics targeting TGF-β superfamily for hematological and autoimmune disorders. Comparable in clinical-stage profile, autoimmune focus, and small-molecule development approach to Kezar.

TypeDirect peer
Description

AnaptysBio is a clinical-stage immunology company developing therapeutics for autoimmune and inflammatory diseases, including IL-36R and PD-1 agonists. Comparable in clinical-stage profile, autoimmune focus, and small-molecule/biologics development model to Kezar.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kezar Life Sciences

Clinical-Stage Biopharmaceuticalskezarlifesciences.com

Kezar Life Sciences firmographics

Firmographics
Name
Kezar Life Sciences
Legal name
Kezar Life Sciences, Inc.
Website
https://kezarlifesciences.com
Company type
Public
Founded year
2015
Operating status
Acquired
Headcount range
11–50 employees
Ownership category
akta.pro rank

Kezar Life Sciences industry classification

Industry
Product category
Clinical-Stage Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Small molecule therapeutics
  • Immunoproteasome inhibitors
  • Autoimmune disease drugs
  • Protein secretion modulators
  • Clinical-stage biotechnology

Where Kezar Life Sciences is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Kezar Life Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Drug Development and Commercialization: Pre-revenue clinical-stage biotechnology company focused on developing small molecule therapeutics for autoimmunity and cancer. The company had no revenue and was operating at a loss as it advanced its pipeline of drug candidates through clinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Kezar Life Sciences product offering

Product offering

Core offering

Kezar Life Sciences is a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics that target protein homeostasis pathways. Its lead candidate, zetomipzomib (KZR-616), is a selective immunoproteasome inhibitor being studied for autoimmune diseases including autoimmune hepatitis, lupus nephritis, and systemic lupus erythematosus. The company also advanced a protein secretion (Sec61 translocon) research program for oncology applications.

Product overview

Kezar Life Sciences was a clinical-stage biotechnology company focused on developing small molecule therapeutics for autoimmunity and cancer. The company's portfolio centered on zetomipzomib (KZR-616), a first-in-class immunoproteasome inhibitor in development for autoimmune hepatitis, lupus nephritis, and systemic lupus erythematosus. Prior to its acquisition by Aurinia Pharmaceuticals, Kezar also maintained a SEC61 inhibitor program (KZR-261) which was sold to Enodia Therapeutics. The company operated at a loss with no revenue and was subsequently acquired in 2026.

Differentiator

Problem solved

Functional benefit

Products and services

  • Zetomipzomib (KZR-616) A first-in-class selective immunoproteasome inhibitor small molecule being evaluated as a therapeutic for autoimmune hepatitis, lupus nephritis, and systemic lupus erythematosus.
  • KZR-261 A small molecule inhibitor of the Sec61 translocon being developed for oncology indications in solid tumors.
  • Sec61 Translocon Research Program A discovery-stage research program developing small molecule modulators of the Sec61 translocon to disrupt protein secretion in disease-driving cells, targeting oncology and immunology indications.

Quantifiable outcome

  • Biochemical remission demonstrated in autoimmune hepatitis patients in Phase 2a PORTOLA trial
  • +2 more outcomes

Companies that use Kezar Life Sciences

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Kezar Life Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Kezar Life Sciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Aurinia PharmaceuticalscoreStrategic or Co-development Partner · 30 March 2026Aurinia Pharmaceuticals acquired Kezar Life Sciences for $6.955 per share in cash plus one non-transferable contingent value right. The acquisition provided Aurinia access to Kezar's lead product candidate zetomipzomib, a first-in-class immunoproteasome inhibitor in development for autoimmune hepatitis, lupus nephritis, and systemic lupus erythematosus. The transaction was expected to close in Q2 2026.
  • Enodia TherapeuticsminorStrategic or Co-development Partner · 12 March 2026Enodia Therapeutics, a Paris-based developer of small-molecule therapies for protein degradation, acquired Kezar's Sec61-based discovery and development program for $1 million upfront plus up to $127 million in potential milestone payments and royalties. The acquisition enabled Enodia to leverage nearly a decade of Kezar's Sec61 translocon research to advance its targeted protein degradation platform.

Scale indicators7 records

Recent moves8 records

Expansion highlights2 records

Kezar Life Sciences competitors and assessment

Company assessment

Broad incumbents

  • Travere Therapeutics: Travere Therapeutics develops therapeutics for rare diseases including FSGS and other immune-mediated kidney conditions. Comparable in addressing serious autoimmune/immune-mediated renal disease and operating as a focused specialty pharmaceutical company in adjacent autoimmune indications.
  • ChemoCentryx: ChemoCentryx developed TAVNEOS (avacopan) for ANCA-associated vasculitis and was acquired by Amgen in 2022. Comparable clinical-stage autoimmune small-molecule company with a similar trajectory from clinical development through acquisition by a larger pharmaceutical company.

Direct peers

  • Cabaletta Bio: Cabaletta is a clinical-stage immunology company developing cell therapies (CAR-T) for autoimmune diseases including lupus nephritis. Like Kezar, it targets autoimmune indications with significant unmet need and operates in the same South San Francisco biotech ecosystem with similar development-stage economics.
  • Aurinia Pharmaceuticals: Aurinia developed and commercialized LUPKYNIS (voclosporin) for lupus nephritis, directly overlapping with Kezar's lead indication. Aurinia is now Kezar's acquirer and will integrate zetomipzomib into its autoimmune franchise, making it the most directly comparable peer in clinical-stage/commercial lupus nephritis drug development.
  • Kyverna Therapeutics: Kyverna is a clinical-stage biotech developing CAR-T cell therapies for autoimmune diseases including lupus nephritis and other immune-mediated disorders. It directly competes with Kezar's lupus nephritis indication using a different modality (cell therapy vs. small molecule).
  • Alpine Immune Sciences: Alpine Immune Sciences developed protein-based immunotherapies for autoimmune and inflammatory diseases, including povetacicept for autoimmune conditions. Acquired by Vertex in 2024 — directly comparable clinical-stage autoimmune biotech with similar acquisition-exit trajectory to Kezar.
  • Keros Therapeutics: Keros Therapeutics is a clinical-stage biotech developing therapeutics targeting TGF-β superfamily for hematological and autoimmune disorders. Comparable in clinical-stage profile, autoimmune focus, and small-molecule development approach to Kezar.
  • AnaptysBio: AnaptysBio is a clinical-stage immunology company developing therapeutics for autoimmune and inflammatory diseases, including IL-36R and PD-1 agonists. Comparable in clinical-stage profile, autoimmune focus, and small-molecule/biologics development model to Kezar.

Emerging players

  • ProKidney: ProKidney is a clinical-stage biotech with limited overlap to Kezar's autoimmune focus but comparable profile as a publicly traded, clinical-stage biotech that underwent restructuring and workforce reductions amid development setbacks.
  • Arcturus Therapeutics: Arcturus Therapeutics is a clinical-stage biotech developing RNA-based therapeutics including for autoimmune and inflammatory diseases. While technology (mRNA vs. small molecule) differs, it shares the clinical-stage autoimmune development profile and public-company structure with Kezar.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Kezar Life Sciences social profiles

Digital presence

Kezar Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kezar Life Sciences leadership team

Management profile

Number of profiles

Kezar Life Sciences funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kezar Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kezar Life Sciences

What does Kezar Life Sciences do?

Kezar Life Sciences is a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics that target protein homeostasis pathways. Its lead candidate, zetomipzomib (KZR-616), is a selective immunoproteasome inhibitor being studied for autoimmune diseases including autoimmune hepatitis, lupus nephritis, and systemic lupus erythematosus. The company also advanced a protein secretion (Sec61 translocon) research program for oncology applications.

Is Kezar Life Sciences a public or private company?

Kezar Life Sciences is a public company. It is classified as public and is currently acquired.

When was Kezar Life Sciences founded?

Kezar Life Sciences was founded in 2015. It employs 11 to 50 people.

Where is Kezar Life Sciences based?

Kezar Life Sciences is headquartered in South San Francisco, United States, in the North America region.

How does Kezar Life Sciences make money?

One revenue line is on record: drug Development and Commercialization.

Who are Kezar Life Sciences's main competitors?

Broad incumbents on record are Travere Therapeutics and ChemoCentryx. Direct peers are Cabaletta Bio, Aurinia Pharmaceuticals, Kyverna Therapeutics, Alpine Immune Sciences, Keros Therapeutics and AnaptysBio. Emerging players are ProKidney and Arcturus Therapeutics.

Does Kezar Life Sciences have an API?

No public API is recorded for Kezar Life Sciences.

What industry is Kezar Life Sciences in?

Kezar Life Sciences's product category is Clinical-Stage Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizAurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life SciencesAurinia Pharmaceuticals Inc. has successfully completed its tender offer for Kezar Life Sciences, with 5,927,580 shares representing 80.24% of Kezar's outstanding shares tendered at $6.955 per share in cash plus one non-transferable contingent value right per share. The aggregate value of the transaction was approximately $41.2 million. Alliance Advisors served as Information Agent on the transaction, which represents the 10th tender offer the firm has successfully completed for pharmaceutical and biotechnology companies in the past 12 months.NewsfileAurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life SciencesAurinia Pharmaceuticals completed its tender offer for Kezar Life Sciences, receiving 5,927,580 shares representing 80.24% of outstanding shares. The offer paid $6.955 per share plus a contingent value right, exceeding the majority threshold. Alliance Advisors served as information agent.GlobeNewswire$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—SILA, LPSN, SKYT, and KZRMonteverde & Associates PC is investigating four merger-related class actions: Sila Realty, LivePerson, Skywater Technology, and Kezar Life Sciences. The proposed deals involve cash and stock payments, with shareholder votes or tender offers scheduled for May 8, 2026.MassbioCEO Innovation Policy Update 04.16.26President Trump signed the Small Business Innovation and Economic Security Act on April 13, restoring SBIR and STTR program funding through September 30, 2031, ending a six-month disruption that had frozen hiring and delayed timelines for Massachusetts biotech companies. FDA regulatory uncertainty is causing significant harm to small biotechs, with Replimune cutting jobs and scaling back U.S. manufacturing after receiving a second Complete Response Letter for its melanoma drug, causing shares to drop 70%, while Kezar Life Sciences was forced into a sale after the FDA canceled a scheduled trial design meeting without explanation. HHS Secretary Robert F. Kennedy Jr. will testify before multiple congressional committees this week and next, providing an opportunity for legislators to question the Administration's health policy priorities, budget proposals, and regulatory direction affecting the biotech industry.PR NewswireAre KZR, EQH, ULYX Obtaining Fair Deals for their Shareholders?Halper Sadeh LLC, an investor rights law firm, announced investigations into three proposed corporate transactions for potential violations of federal securities laws or breaches of fiduciary duties to shareholders. The transactions under scrutiny include Kezar Life Sciences' sale to Aurinia Pharmaceuticals for $6.955 per share plus contingent value rights, Equitable Holdings' merger with Corebridge Financial where Equitable shareholders would own approximately 49% of the combined company, and Urgent.ly's sale to Agero for $5.50 per share.Defense WorldKezar Life Sciences, Inc. (NASDAQ:KZR) Given Average Recommendation of “Reduce” by BrokeragesSix brokerage firms have assigned an average 'Reduce' recommendation to Kezar Life Sciences (NASDAQ:KZR), with two analysts issuing sell ratings and four assigning hold ratings, and an average 12-month target price of $6.00. The company's stock opened at $7.35 with a market cap of $54.17 million, and it reported quarterly earnings of -$1.99 per share, missing consensus estimates by $0.60. Multiple institutional investors, including BML Capital Management, Bridgeway Capital Management, and State Street Corp, increased their stakes in the company during the third and fourth quarters.GlobeNewswire$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—KZR, CNTA, TALK, and WBDMonteverde & Associates PC, a New York-based securities class action law firm, announced ongoing investigations into four pending mergers on behalf of shareholders. The investigated transactions include Kezar Life Sciences' sale to Aurinia Pharmaceuticals for $6.955 per share plus contingent value rights, Centessa Pharmaceuticals' sale to Eli Lilly for $38.00 per share plus up to $9.00 in milestone payments, Talkspace's sale to Universal Health Services for $5.25 per share, and Warner Bros. Discovery's sale to Paramount Skydance Corporation for $31.00 per share plus a ticking fee. The law firm is soliciting shareholders of these companies to contact them regarding concerns about the fairness of the proposed transactions.GlobeNewswireShareholder Alert: Ademi LLP investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public ShareholdersLaw firm Ademi LLP announced an investigation into Kezar Life Sciences (NASDAQ: KZR) regarding its recently announced transaction with Aurinia, alleging possible breaches of fiduciary duty and other violations of law. Under the deal terms, Kezar stockholders would receive $6.955 in cash per share plus one contingent value right tied to future payments from drug development programs and collaborations. The firm claims the transaction agreement unreasonably limits competing transactions by imposing significant penalties on Kezar if it accepts a competing bid.PR NewswireAre KZR, TALK, WBD Obtaining Fair Deals for their Shareholders?Investor rights law firm Halper Sadeh LLC announced investigations into three proposed acquisitions for potential violations of federal securities laws and breaches of fiduciary duties to shareholders. The transactions under scrutiny include Kezar Life Sciences' sale to Aurinia Pharmaceuticals for $6.955 per share plus contingent value rights, Talkspace's sale to Universal Health Services for $5.25 per share, and Warner Bros. Discovery's sale to Paramount Skydance Corporation for $31.00 per share in cash. The law firm is soliciting affected shareholders to discuss their legal rights and options at no cost.STATHow a four-month FDA delay forced a small biotech company to close its doorsKezar Life Sciences, a small biotech company, was forced to shut down after the FDA abruptly canceled a critical meeting last October without explanation, delaying the company's clinical trial plan for its autoimmune hepatitis treatment by four months. The company lost investor confidence during this period, laid off its staff of about 60 people, and was ultimately sold to Aurinia Pharmaceuticals. CEO Chris Kirk criticized the FDA's inconsistent decision-making and staff departures as harmful to the biotech ecosystem and patients.